Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib

Jae Hoon Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Hyo Jung Seo, Jong Doo Lee, Hye Jin Choi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F-2-fluoro-2-deoxyglucose ( 18F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. Materials and methods: A total of 29 patients with HCC were included. Baseline 18F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. Results: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). Conclusion: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.

Original languageEnglish
Pages (from-to)1144-1149
Number of pages6
JournalLiver International
Volume31
Issue number8
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Hepatocellular Carcinoma
Disease-Free Survival
Survival
Confidence Intervals
Fetal Proteins
sorafenib
Portal Vein
Thrombosis
Therapeutics
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{66f7fe53818a49d19b828d03849f2170,
title = "Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib",
abstract = "Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F-2-fluoro-2-deoxyglucose ( 18F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. Materials and methods: A total of 29 patients with HCC were included. Baseline 18F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. Results: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95{\%} confidence interval (CI): 0.0-12.0] and 3.8 months (95{\%} CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). Conclusion: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.",
author = "Lee, {Jae Hoon} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Seo, {Hyo Jung} and Lee, {Jong Doo} and Choi, {Hye Jin}",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1478-3231.2011.02541.x",
language = "English",
volume = "31",
pages = "1144--1149",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "8",

}

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. / Lee, Jae Hoon; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Seo, Hyo Jung; Lee, Jong Doo; Choi, Hye Jin.

In: Liver International, Vol. 31, No. 8, 01.09.2011, p. 1144-1149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib

AU - Lee, Jae Hoon

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Seo, Hyo Jung

AU - Lee, Jong Doo

AU - Choi, Hye Jin

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F-2-fluoro-2-deoxyglucose ( 18F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. Materials and methods: A total of 29 patients with HCC were included. Baseline 18F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. Results: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). Conclusion: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.

AB - Background: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used 18F-2-fluoro-2-deoxyglucose ( 18F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. Materials and methods: A total of 29 patients with HCC were included. Baseline 18F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. Results: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). Conclusion: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.

UR - http://www.scopus.com/inward/record.url?scp=79961207010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961207010&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2011.02541.x

DO - 10.1111/j.1478-3231.2011.02541.x

M3 - Article

C2 - 21745288

AN - SCOPUS:79961207010

VL - 31

SP - 1144

EP - 1149

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 8

ER -